Combination strategies for first-line treatment of patients with unresectable hepatocellular carcinoma: prospect of natural products
作者机构:School of Basic Medical Sciences Chengdu University State Key Laboratory of Quality Research in Chinese Medicine Institute of Chinese Medical Sciences University of Macau Department of Pharmaceutical Sciences Faculty of Health Sciences University of Macau
出 版 物:《Chinese Journal of Natural Medicines》 (中国天然药物(英文版))
年 卷 期:2024年第01期
页 面:1-3页
核心收录:
学科分类:1008[医学-中药学(可授医学、理学学位)] 1006[医学-中西医结合] 100602[医学-中西医结合临床] 10[医学]
基 金:supported by the Science and Technology Development Fund,Macau SAR (No. 0053-2021-AGJ) the Internal Research Grant of the State Key Laboratory of Quality Research in Chinese Medicine,University of Macau (No. SKL-QRCM-IRG2023-011) the Natural Science Foundation of Sichuan Province (No. 2023NSFSC1783)
摘 要:Liver cancer stands as a significant global health concern, contributing substantially to cancer incidence and mortality, particularly in Asian countries[1]. Hepatocellular carcinoma(HCC) accounts for approximately 90% of all liver cancer cases and is characterized by a high-risk profile and a generally poor prognosis[2]. To address advanced HCC, systemic therapy has been recommended, leading to the approval of a range of treatment regimens in clinical practice.